Chronic Kidney Disease
Pipeline by Development Stage
Drug Modality Breakdown
Chronic Kidney Disease is a $13.3B market (indication-attributable estimate) in mature/consolidating phase, dominated by two SGLT2 inhibitors representing 94% of spending.
Key Trends
- SGLT2 inhibitors (dapagliflozin, empagliflozin) have become standard of care, driving 94% of Part D spend
- Legacy phosphate binders and vitamin D analogs face patent cliffs 2030–2031, opening biosimilar/generic opportunities
- 590 active trials signal robust pipeline activity, with 129 Phase 3 trials testing new mechanisms in CKD progression and mineral metabolism
Career Verdict
Strong career opportunity: mature market with high revenue, stable patient base, but limited blockbuster upside; ideal for those seeking established companies, commercial scale, and MSL/medical affairs roles rather than high-growth innovation bets.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | Empagliflozin (JARDIANCE, indication: CKD) | Boehringer Ingelheim / Eli Lilly | $8.8B | 66% | Peak | Stable | |
| 2 | Dapagliflozin (FARXIGA, indication: CKD) | AstraZeneca | $4.3B | 32% | Peak | Stable | |
| 3 | Finerenone (KERENDIA, indication: CKD) | Bayer | $1.1B | 8% | Peak | Growing |
Drug Class Breakdown
Dominant; standard of care for CKD with albuminuria
Niche; often combined with SGLT2i for additional renal protection
Legacy segment; facing patent cliffs and generic pressure
Supportive care; addresses CKD-related anemia
Minimal revenue; older mechanism
Career Outlook
StableCKD is a stable, high-revenue therapeutic area with limited growth but strong employment depth. SGLT2i dominance creates a bifurcated market: established players (AstraZeneca, Boehringer Ingelheim, Bayer) have secure footing and premium compensation, while legacy businesses (Sanofi, Fresenius) face erosion. Best career moves are into Commercial, Medical Affairs, and Real-World Evidence roles at market leaders; R&D specialists should focus on pipeline programs (Phase 2–3 trials) rather than legacy portfolio maintenance.
Breaking In
Aim for roles at AstraZeneca, Boehringer Ingelheim, or Abbott; start in Commercial or Clinical Operations to learn the stable CKD market, then pivot to Medical Affairs if you build nephrology expertise.
For Experienced Professionals
If 5+ years in pharma, CKD Medical Affairs or Market Access roles at established leaders offer $280K+; avoid legacy businesses facing patent cliffs unless seeking a 2–3 year wind-down role with restructuring experience.
In-Demand Skills
Best For
Hiring Landscape
CKD hiring is concentrated in commercial (1,420 jobs, avg $232K) and engineering (831 jobs, avg $205K), reflecting mature-market focus on sales execution, market access, and digital health platforms rather than discovery. Abbott, AbbVie, Takeda, and AstraZeneca lead hiring (1,029–1,499 jobs each); Medical Affairs roles command highest salary ($302K) due to complex KOL relationships in nephrology.
By Department
Commercial and Medical Affairs roles offer best near-term hiring and highest compensation; R&D and Manufacturing roles are smaller and may contract as legacy products face patent cliffs.
On Market (8)
Approved therapies currently available
Competitive Landscape
59 companies ranked by most advanced pipeline stage
+29 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 26,476 patients across 50 trials
Role of Finerenone in African American Veterans With Diabetic Kidney Disease
Safety of Short-course of NSAIDs in Pediatric Patients With CKD
A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease
Nitrite-boosting Therapy for Improving Physiological Function in Patients With Chronic Kidney Disease
Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C
Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia
The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate
Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D
Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)
Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease
Vitamin D and Coronary Calcification Study
Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v.
Anti-Oxidant Therapy In Chronic Renal Insufficiency (ATIC) Study
Growth Hormone Treatment in Infants Aged 1 to 2 Years With Chronic Renal Insufficiency (CRI) and Growth Retardation.
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects
EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)
A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease
Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients
Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease
Clinical Efficacy of Two Erythropoietin Drug in Participants With Secondary Anemia to Chronic Kidney Disease.
Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002
Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis
The Water Intake Trial: Pilot Phase
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)
PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease
A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis
A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis
Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease
Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients
Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis
The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4
The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis
A Study of Iron Oligosaccharide in Chronic Kidney Disease Patients
Study to Demonstrate Equivalence of Sevelamer Carbonate Powder and Sevelamer HCl Tablets in Haemodialysis Patients
GLUcose Transport and REnalPROtection in Chronic Kidney Disease
Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)
Vitamin-D Receptor Activation (VDRA) in Chronic Kidney Disease
Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease
Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
Related Jobs in Nephrology
QC Microbiology Analyst 3
Senior Principal System Architect - Digital Ecosystem Coronary and Renal Denervation CRDN
Principal Clinical Specialist - Coronary Renal Devernation - San Francisco, CA
Nephrology Launch Lead, International
Principal Clinical Specialist, Coronary Renal Devernation - Portland, OR
Clinical Research Specialsit
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.